文献速递乳腺癌放疗放疗物理与技术

NRG Oncology RTOG 0319长期更新:3D-CRT加速部分乳腺照射治疗I-II期乳腺癌的1/2期试验

Long-Term Update of NRG Oncology RTOG 0319: A Phase 1 and 2 Trial to Evaluate 3-Dimensional Conformal Radiation Therapy Confined to the Region of the Lumpectomy Cavity for Stage I and II Breast Carcinoma.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2016-09-03

该1/2期试验评估3D-CRT加速部分乳腺照射(APBI)治疗I-II期乳腺癌的长期毒性与疗效,52例可评估患者接受38.5 Gy/10次/5天方案,中位随访8年,7年孤立同侧乳腺复发率5.9%,3级治疗相关不良事件7.7%,无3级疼痛、肺或心脏毒性。

要点

  • 7年孤立同侧乳腺复发率为5.9%,所有同侧乳腺复发均为浸润性。
  • 7年无乳房切除生存率、无病生存率和总生存率分别为71.2%、71.2%和78.8%。
  • 3级治疗相关不良事件报告率为7.7%,未报告3级疼痛、肺或心脏毒性。

核心结论

  • 3D-CRT APBI在长期随访中显示持久的肿瘤控制和较低的3级毒性,与其他APBI技术相当。

研究设计与样本

  • NRG Oncology RTOG 0319为美国首个评估3D-CRT APBI的合作组1/2期试验,纳入I-II期浸润性乳腺癌患者(肿瘤≤3 cm、阳性淋巴结≤3个、切缘阴性),方案为38.5 Gy分10次每日两次照射。
  • 共58例入组,52例符合条件,中位年龄61岁,94%为I期,83%为雌激素受体阳性,中位随访8年(范围1.7-9.0年)。

主要发现

  • 7年孤立同侧乳腺复发(无远处转移)估计值为5.9%;7年所有同侧乳腺复发、同侧淋巴结复发、乳房切除率和远处转移估计值分别为7.7%、5.8%、7.7%和7.7%。
  • 4例同侧乳腺复发均为浸润性,其中3例有成分位于计划靶体积内;失败模式包括3例同侧乳腺复发、1例同侧淋巴结复发、2例远处转移、1例同侧淋巴结复发+远处转移、1例同侧乳腺复发+同侧淋巴结复发+远处转移。
  • 4例患者(7.7%)报告3级治疗相关不良事件,未报告3级疼痛、肺或心脏毒性。

关键数值与推荐

  • 3D-CRT APBI处方剂量为38.5 Gy分10次每日两次。
  • 不良事件采用CTCAE v3.0分级。

临床怎么用

  • 对于符合条件的I-II期乳腺癌患者,3D-CRT APBI可作为加速部分乳腺照射的一种非侵入性选择,长期数据显示肿瘤控制持久且3级毒性低。
  • 需等待成熟的3期试验结果以确定该技术的适用性和局限性。

局限性

  • 本文为1/2期试验的长期更新,样本量有限(52例可评估),非随机对照设计。
  • 作者指出需等待成熟的3期结果来确定该非侵入性APBI技术的适用性和局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: NRG Oncology RTOG 0319 was the first cooperative group trial in the United States to evaluate 3-dimensional conformal radiation therapy (3D-CRT) accelerated partial breast irradiation (APBI). This report updates secondary endpoints of toxicity and efficacy. METHODS AND MATERIALS: Patients with stage I or II invasive breast cancer (tumor size ≤3 cm, ≤3 positive lymph nodes, negative margins) were eligible for 3D-CRT APBI: 38.5 Gy in 10 twice-daily fractions. Patient characteristics and treatment details have previously been reported. Adverse events were graded with CTCAE v3.0 (National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0). This analysis updates the rates of ipsilateral breast recurrence (IBR), contralateral breast recurrence, ipsilateral node recurrence (INR), metastatic sites (distant metastases [DM]), mastectomy, disease-free survival, mastectomy-free survival, and overall survival. RESULTS: Of 58 enrolled patients, 52 were eligible, with a median age of 61 years; 94% had stage I cancer and 83% had estrogen receptor positive disease. The median follow-up period was 8 years (minimum-maximum, 1.7-9.0 years). The 7-year estimate of isolated IBR (no DM) was 5.9%. The 7-year estimates of all IBRs, INR, mastectomy rate, and DM were 7.7%, 5.8%, 7.7%, and 7.7%, respectively. All 4 IBRs were invasive, of which 3 had a component within the planning target volume. The patterns of failure were as follows: 3 IBRs, 1 INR, 2 DM, 1 INR plus DM, and 1 IBR plus INR plus DM. The 7-year estimates of mastectomy-free survival, disease-free survival, and overall survival were 71.2%, 71.2%, and 78.8%, respectively. Thirteen patients died: 3 of breast cancer and 10 of other causes. Grade 3 (G3) treatment-related adverse events were reported by 4 patients (7.7%). No G3 pain or pulmonary or cardiac toxicities were reported. CONCLUSIONS: This phase 1 and 2 trial of 3D-CRT APBI continues to show durable tumor control and minimal G3 toxicity, comparable to other APBI techniques. Mature phase 3 results will determine the appropriateness and limitations of this noninvasive APBI technique.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Rabinovitch R, Moughan J, Vicini F, et al. Long-Term Update of NRG Oncology RTOG 0319: A Phase 1 and 2 Trial to Evaluate 3-Dimensional Conformal Radiation Therapy Confined to the Region of the Lumpectomy Cavity for Stage I and II Breast Carcinoma. Int J Radiat Oncol Biol Phys. 2016. PMID: 27869081. doi:10.1016/j.ijrobp.2016.08.042

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。